These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12324291)

  • 1. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men.
    Larsen TM; Toubro S; van Baak MA; Gottesdiener KM; Larson P; Saris WH; Astrup A
    Am J Clin Nutr; 2002 Oct; 76(4):780-8. PubMed ID: 12324291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects.
    Buemann B; Toubro S; Astrup A
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1553-60. PubMed ID: 11126205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.
    Redman LM; de Jonge L; Fang X; Gamlin B; Recker D; Greenway FL; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2007 Feb; 92(2):527-31. PubMed ID: 17118998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.
    Alemzadeh R; Karlstad MD; Tushaus K; Buchholz M
    Metabolism; 2008 Nov; 57(11):1597-607. PubMed ID: 18940400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
    Weyer C; Tataranni PA; Snitker S; Danforth E; Ravussin E
    Diabetes; 1998 Oct; 47(10):1555-61. PubMed ID: 9753292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men.
    van Baak MA; Hul GB; Toubro S; Astrup A; Gottesdiener KM; DeSmet M; Saris WH
    Clin Pharmacol Ther; 2002 Apr; 71(4):272-9. PubMed ID: 11956510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.
    Karhunen L; Franssila-Kallunki A; Rissanen P; Valve R; Kolehmainen M; Rissanen A; Uusitupa M
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1567-72. PubMed ID: 11126207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a novel beta-adrenoceptor agonist (Ro 40-2148) on resting energy expenditure in obese women.
    Haesler E; Golay A; Güzelhan C; Schutz Y; Hartmann D; Jéquier E; Felber JP
    Int J Obes Relat Metab Disord; 1994 May; 18(5):313-22. PubMed ID: 7914795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of oils containing triacylglycerols and medium-chain fatty acids in the dietary treatment of obesity. The effect on resting energy expenditure and serum lipids].
    Hainer V; Kunesová M; Stich V; Zák A; Parizková J
    Cas Lek Cesk; 1994 Jun; 133(12):373-5. PubMed ID: 8069895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin levels are associated with fat oxidation and dietary-induced weight loss in obesity.
    Verdich C; Toubro S; Buemann B; Holst JJ; Bülow J; Simonsen L; Søndergaard SB; Christensen NJ; Astrup A
    Obes Res; 2001 Aug; 9(8):452-61. PubMed ID: 11500525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body fat oxidation rate and plasma triacylglycerol concentrations in men consuming an ad libitum high-carbohydrate or low-carbohydrate diet.
    Landry N; Bergeron N; Archer R; Samson P; Corneau L; Bergeron J; Dériaz O
    Am J Clin Nutr; 2003 Mar; 77(3):580-6. PubMed ID: 12600846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of diurnal Ramadan fasting on energy expenditure and substrate oxidation in healthy men.
    Alsubheen SA; Ismail M; Baker A; Blair J; Adebayo A; Kelly L; Chandurkar V; Cheema S; Joanisse DR; Basset FA
    Br J Nutr; 2017 Dec; 118(12):1023-1030. PubMed ID: 29198194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women.
    Alger S; Larson K; Boyce VL; Seagle H; Fontvieille AM; Ferraro RT; Rising R; Ravussin E
    Am J Clin Nutr; 1993 Feb; 57(2):120-6. PubMed ID: 8424378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on metabolic rate and fuel selection of a selective beta-3 agonist (ICI D7114) in healthy lean men.
    Goldberg GR; Prentice AM; Murgatroyd PR; Haines W; Tuersley MD
    Int J Obes Relat Metab Disord; 1995 Sep; 19(9):625-31. PubMed ID: 8574272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the type of dietary fat on postprandial fat oxidation rates: monounsaturated (olive oil) vs saturated fat (cream).
    Piers LS; Walker KZ; Stoney RM; Soares MJ; O'Dea K
    Int J Obes Relat Metab Disord; 2002 Jun; 26(6):814-21. PubMed ID: 12037652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of body composition, substrates, and hormones to the variability in energy expenditure and substrate utilization in premenopausal women.
    Astrup A; Buemann B; Christensen NJ; Madsen J; Gluud C; Bennett P; Svenstrup B
    J Clin Endocrinol Metab; 1992 Feb; 74(2):279-86. PubMed ID: 1530952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sibutramine on energy expenditure and body composition in obese adolescents.
    Van Mil EG; Westerterp KR; Kester AD; Delemarre-van de Waal HA; Gerver WJ; Saris WH
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1409-14. PubMed ID: 17264187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.